Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Insulin Glargine s.c. Once Daily in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Inadequately Controlled on 1-3 Oral Glucose-lowering Medications (AMBITION 7)

NCT07797335 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07797335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07797335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Insulin Glargine s.c. Once Daily in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Inadequately Controlled on 1-3 Oral Glucose-lowering Medications (AMBITION 7)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Recruiting
Start date
August 24, 2026
Completion date
September 20, 2028
Enrollment
1,778 (estimated)
Sites
330

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular risk, type 2 diabetes